<DOC>
	<DOC>NCT02206308</DOC>
	<brief_summary>The purpose of this study is to determine whether SCT400 is safe and effective in the treatment of B-cell Non Hodgkin's lymphoma</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>aged from 18 to 75 years having histologically confirmed NHL expressing CD20 antigen having relapsed nonHodgkin's lymphoma(NHL) after at least one prior course of standard therapy Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 according to WHO scale, and expected survival of at least ≥ 3 months signed an informed consent form which was approved by the institutional review board of the respective medical center single measurable lesion ≥7 cm in diameter with serious hematologic dysfunction (white blood cell count of &lt;3.0×103/μL; absolute neutrophil count of &lt;1.5×103/ μL; platelet count of &lt; 75×103/μL; hemoglobin level of &lt; 8.0 g/dL; serum immunoglobulin G(IgG) level of &lt;600 mg/dL);, hepatic dysfunction (total bilirubin level of &gt; 1.5×upper limit of normal（ULN）; aspartate amino transferase (AST) and alanine amino transferase (ALT) levels of &gt;2.5 × ULN (≥5 × ULN for patients with liver metastases)); and renal dysfunction (serum creatinine level of &gt; 1.5×ULN ) having to be at least 4 weeks beyond prior anticancer therapy including corticosteroid, or participating in other clinical trial or have not recovered from significant toxicities of prior therapy had received rituximab or other antiCD20(+) monoclonal antibody treatment within 1 year before enrollment had received hematopoietic cytokines, e.g CSF、EPO within 1 week prior to study entry with other malignancies ; or central nervous system (CNS) lymphoma, AIDS related lymphoma; or active opportunistic infection, a serious nonmalignant disease having hepatitis B virus surface antigen and /or antibodies to hepatitis C virus or human immunodeficiency virus with pleural effusions or ascites secondary to lymphoma; or high risk of tumor lysis syndrome; or recent major surgery (within 28 days ) with a history of allergic reaction or protein product allergy including murine proteins pregnant or lactating or not accepted birth control methods including male patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Chimeric anti-CD20 monoclonal antibody(SCT400)</keyword>
	<keyword>escalating doses</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics and pharmacodynamics</keyword>
</DOC>